Cargando…

Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome

Detalles Bibliográficos
Autores principales:	File, Danielle M., Morgan, Katherine P., Khagi, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2020
Materias:	Molecular Tumor Board
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446372/ https://www.ncbi.nlm.nih.gov/pubmed/32923878 http://dx.doi.org/10.1200/PO.20.00112

Ejemplares similares

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2‐Year Durable Response
por: Valiakhmetova, Andge, et al.
Publicado: (2019)

Olaparib in the Setting of Radiotherapy-Associated Sarcoma: What Can Precision Medicine Offer For Rare Cancers?
por: Hamdan, Diaddin, et al.
Publicado: (2023)

Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation
por: Hou, Zhiwei, et al.
Publicado: (2023)

Using Advanced Molecular Profiling to Identify the Origin of and Tailor Treatment for an Intracranial Mass of Unknown Primary
por: Martinez, Francisco, et al.
Publicado: (2021)

Infantile ZFTA Fusion–Positive Tumor of the Posterior Fossa: Molecular Tumor Board
por: Paulson, Vera A., et al.
Publicado: (2023)

Longitudinal Molecular Analysis of Tumor Exome and Transcriptome to Evaluate Clonal Evolution and Identify Novel Therapeutic Targets in Thymoma
por: Nabel, Christopher S., et al.
Publicado: (2023)

Sustained and durable response with Alisertib monotherapy in the treatment of relapsed Atypical Teratoid Rhabdoid Tumor (ATRT)
por: Howden, Kaitlyn, et al.
Publicado: (2022)

Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD‐1/PDL‐1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer
por: Winer, Arthur, et al.
Publicado: (2019)

Intracranial myxoid mesenchymal neoplasms with EWSR1 gene rearrangement: report of 2 midline cases with one demonstrating durable response to MET inhibitor monotherapy
por: De Los Santos, Yanel, et al.
Publicado: (2021)

Primary glioblastoma of the cauda equina with molecular and histopathological characterization: Case report
por: Langston, Rebekah G, et al.
Publicado: (2021)

The experience of successful treatment of ETV6-NTRK3-positive infant glioblastoma with entrectinib
por: Papusha, Ludmila, et al.
Publicado: (2021)

Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma
por: Grogan, Patrick T, et al.
Publicado: (2022)

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
por: Fulton, Ben, et al.
Publicado: (2017)

Sporadic adamantinomatous craniopharyngioma with double-hit somatic APC mutations
por: Hong, Christopher S, et al.
Publicado: (2021)

Use of circulating tumor DNA to guide treatment of primary central nervous system lymphoma: a case report
por: Ho, Ka-wai Grace, et al.
Publicado: (2021)

H3K27M-mutant, hemispheric diffuse glioma in an adult patient with prolonged survival
por: Chia, Noel, et al.
Publicado: (2021)

Spontaneous regression of a congenital high-grade glioma—a case report
por: Riedmeier, Maria, et al.
Publicado: (2021)

Anaplastic pleomorphic xanthoastrocytoma with epithelioid morphology misdiagnosed and treated as melanoma
por: Dorostkar, Mario M, et al.
Publicado: (2022)

Markedly prolonged disease course, with breakthrough seizures, in a glioma with an isolated IDH1 mutation
por: Drumm, Michael, et al.
Publicado: (2022)

Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient
por: McCord, Matthew, et al.
Publicado: (2021)

Bone metastases in an adult patient with diffuse midline glioma: a case report
por: Li, Shaoqun, et al.
Publicado: (2020)

Utility of [18F]-fluoroestradiol (FES) PET/CT with dedicated brain acquisition in differentiating brain metastases from posttreatment change in estrogen receptor-positive breast cancer
por: Ivanidze, Jana, et al.
Publicado: (2021)

IDH-mutant astrocytoma with EGFR amplification—Genomic profiling in four cases and review of literature
por: Umphlett, Melissa, et al.
Publicado: (2022)

Infantile suprasellar tumor diagnosed as a pineoblastoma RB1 subgroup and treatment challenges: A pediatric SNO Molecular Tumor Board
por: Rubens, Jeffrey A, et al.
Publicado: (2022)

An unusual case of atypical teratoid/rhabdoid tumor, initially diagnosed as atypical pituitary adenoma in a 13-year-old male patient
por: Ronsley, Rebecca, et al.
Publicado: (2022)

Diagnostics and prospective outcome of a diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters after surgical resection (DGONC): a case report
por: Howie, Chelsea, et al.
Publicado: (2022)

A case (report) for mechanistic validation of meningioma molecular therapies
por: Nguyen, Minh P, et al.
Publicado: (2022)

MYO5A::FGFR1 represents a novel fusion event in pediatric low-grade glioma
por: Galvin, Robert T, et al.
Publicado: (2023)

Metastatic high-grade meningioma: A case report and review of risk factors for metastasis
por: Bailey, Destiny D, et al.
Publicado: (2023)

Intracranial mesenchymal tumor, FET::CREB fusion-positive in the lateral ventricle
por: Ozkizilkaya, Hanim I, et al.
Publicado: (2023)

Diffuse leptomeningeal glioneuronal tumor in a child masquerading as an intramedullary spinal pilocytic astrocytoma
por: Madsen, Peter J, et al.
Publicado: (2023)

A case of midbrain germinoma: A literature review for radiographic and clinical features
por: Miyake, Yohei, et al.
Publicado: (2023)

Plexiform neurofibroma of the liver, with malignant transformation to MPNST, in a pediatric patient without neurofibromatosis type 1
por: Ioannou, Maria, et al.
Publicado: (2023)

Embryonal tumor with multilayered rosettes: Overview of diagnosis and therapy
por: Chadda, Karan R, et al.
Publicado: (2023)

VRK1 Depletion Facilitates the Synthetic Lethality of Temozolomide and Olaparib in Glioblastoma Cells
por: Navarro-Carrasco, Elena, et al.
Publicado: (2021)

SPDR-05 PARP INHIBITORS RESTORE TEMOZOLOMIDE SENSITIVITY IN MSH6-DEFICIENT TEMOZOLOMIDE-RESISTANT GLIOBLASTOMA CELLS
por: Higuchi, Fumi, et al.
Publicado: (2019)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial
por: Hanna, Catherine, et al.
Publicado: (2020)

Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells
por: Zampieri, Luca X., et al.
Publicado: (2021)

Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer
por: Stanzione, Marcello, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lbc5oi7o5ttqkplesugar3uru5